URGN Stock Forecast 2025-2026
Distance to URGN Price Targets
URGN Price Momentum
10 Quality Stocks Worth Considering Now
Researching UroGen (URGN) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on URGN and similar high-potential opportunities.
Latest URGN Stock Price Targets & Analyst Predictions
Based on our analysis of 11 Wall Street analysts, URGN has a bullish consensus with a median price target of $35.00 (ranging from $22.00 to $55.00). The overall analyst rating is Strong Buy (9.1/10). Currently trading at $11.38, the median forecast implies a 207.6% upside. This outlook is supported by 6 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Raghuram Selvaraju at HC Wainwright & Co., projecting a 383.3% upside. Conversely, the most conservative target is provided by Leland Gershell at Oppenheimer, suggesting a 93.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
URGN Analyst Ratings
URGN Price Target Range
Latest URGN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for URGN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 13, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $25.00 |
| Mar 11, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $55.00 |
| Mar 10, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $25.00 |
| Feb 25, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $64.00 |
| Feb 20, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $25.00 |
| Feb 19, 2025 | Ladenburg Thalmann | Aydin Huseynov | Buy | Assumes | $31.00 |
| Feb 18, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $25.00 |
| Feb 12, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $25.00 |
| Jan 23, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $25.00 |
| Jan 15, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $25.00 |
| Dec 6, 2024 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $25.00 |
| Nov 6, 2024 | EF Hutton | Jason Kolbert | Buy | Maintains | $25.00 |
| Oct 29, 2024 | EF Hutton | Jason Kolbert | Buy | Maintains | $25.00 |
| Oct 21, 2024 | EF Hutton | Jason Kolbert | Buy | Maintains | $25.00 |
| Oct 16, 2024 | EF Hutton | Jason Kolbert | Buy | Maintains | $25.00 |
| Oct 16, 2024 | Oppenheimer | Leland Gershell | Outperform | Reiterates | $40.00 |
| Oct 16, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $64.00 |
| Oct 15, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $60.00 |
| Oct 14, 2024 | EF Hutton | Jason Kolbert | Buy | Initiates | $25.00 |
| Oct 3, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $60.00 |
Urogen Pharma Ltd. (URGN) Competitors
The following stocks are similar to UroGen based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Urogen Pharma Ltd. (URGN) Financial Data
Urogen Pharma Ltd. has a market capitalization of $548.52M with a P/E ratio of 0.0x. The company generates $90.40M in trailing twelve-month revenue with a -140.4% profit margin.
Revenue growth is +4.4% quarter-over-quarter, while maintaining an operating margin of -108.1% and return on equity of +1,441.3%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Urogen Pharma Ltd. (URGN) Business Model
About Urogen Pharma Ltd.
Develops therapies for urological diseases.
Urogen Pharma generates revenue by developing and commercializing innovative drug-delivery systems for urological and uro-oncological diseases, primarily targeting unmet medical needs in the oncology space. Their proprietary RTGel™ technology allows for enhanced drug release and retention, resulting in more effective and less invasive treatment options.
The company focuses on conditions such as low-grade upper tract urothelial carcinoma and non-muscle invasive bladder cancer, aiming to transform the treatment landscape in urology. With headquarters in Princeton, New Jersey, and Tamworth, UK, Urogen Pharma is positioned as a leader in medical advancements, providing critical solutions to patients and healthcare providers worldwide.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
235
CEO
Ms. Elizabeth A. Barrett
Country
United States
IPO Year
2017
Website
www.urogen.comUrogen Pharma Ltd. (URGN) Latest News & Analysis
UroGen Pharma Ltd. (NASDAQ: URGN) will hold its Q4 2024 earnings conference call on March 10, 2025, at 10:00 AM ET, featuring key company executives.
UroGen Pharma's upcoming earnings call may reveal key financial performance metrics and strategic insights, influencing investor sentiment and stock valuation.
UroGen Pharma Ltd. (Nasdaq: URGN) reported its Q4 and full-year 2024 financial results, highlighting significant achievements in its commercial business and pipeline development.
UroGen Pharma's financial results and strategic developments signal growth potential, impacting stock performance and investor confidence in the biotech sector.
Urogen Pharma (URGN) reported a quarterly loss of $0.80 per share, worse than the expected loss of $0.74 and compared to a loss of $0.72 per share a year prior.
Urogen Pharma's larger-than-expected quarterly loss may signal ongoing financial struggles, potentially impacting investor confidence and stock performance.
UroGen Pharma Ltd. granted inducement RSUs to 7 new employees to support the commercialization of Jelmyto®, its first approved product for treating urothelial cancer.
The hiring of new employees and RSU grants indicate UroGen's commitment to growth and commercialization of Jelmyto®, potentially impacting future revenue and stock performance.
UroGen Pharma to Report Fourth Quarter and Full-Year 2024 Financial Results on Monday, March 10, 2025
27 days agoUroGen Pharma Ltd. (Nasdaq: URGN) will report Q4 and full-year 2024 financial results on March 10, 2025, followed by a conference call at 10:00 AM ET.
UroGen Pharma's upcoming earnings report could significantly impact stock performance, offering insights into financial health and future growth potential, crucial for investment decisions.
UroGen Pharma Ltd. (Nasdaq: URGN) will participate in a fireside chat at the TD Cowen Health Care Conference on March 3, 2025, at 1:50 PM ET in Boston, MA.
UroGen Pharma's participation in a prominent healthcare conference signals potential visibility and engagement with investors, which may influence stock performance and investor sentiment.
Frequently Asked Questions About URGN Stock
What is Urogen Pharma Ltd.'s (URGN) stock forecast for 2025?
Based on our analysis of 11 Wall Street analysts, Urogen Pharma Ltd. (URGN) has a median price target of $35.00. The highest price target is $55.00 and the lowest is $22.00.
Is URGN stock a good investment in 2025?
According to current analyst ratings, URGN has 6 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $11.38. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for URGN stock?
Wall Street analysts predict URGN stock could reach $35.00 in the next 12 months. This represents a 207.6% increase from the current price of $11.38. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Urogen Pharma Ltd.'s business model?
Urogen Pharma generates revenue by developing and commercializing innovative drug-delivery systems for urological and uro-oncological diseases, primarily targeting unmet medical needs in the oncology space. Their proprietary RTGel™ technology allows for enhanced drug release and retention, resulting in more effective and less invasive treatment options.
What is the highest forecasted price for URGN Urogen Pharma Ltd.?
The highest price target for URGN is $55.00 from Raghuram Selvaraju at HC Wainwright & Co., which represents a 383.3% increase from the current price of $11.38.
What is the lowest forecasted price for URGN Urogen Pharma Ltd.?
The lowest price target for URGN is $22.00 from Leland Gershell at Oppenheimer, which represents a 93.3% increase from the current price of $11.38.
What is the overall URGN consensus from analysts for Urogen Pharma Ltd.?
The overall analyst consensus for URGN is bullish. Out of 11 Wall Street analysts, 6 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $35.00.
How accurate are URGN stock price projections?
Stock price projections, including those for Urogen Pharma Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
